A PYMNTS Company

US: Sanofi buys Synthorx for $2.5B

By  |  December 9, 2019

Sanofi has agreed to buy cancer biotech company Synthorx for $2.5 billion, the first big move by new Chief Executive Paul Hudson to reinvigorate the sprawling French health-care giant.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The company has a long history in cancer-drug development but has fallen behind in the latest rush to develop immunotherapies, or drugs that help the immune system fight tumors. Its acquisition of Synthorx is a bet that it can make up that ground.

    Synthorx, based in La Jolla, Calif., is developing a drug that aims to boost the immune system’s response to cancer. The drug is in the early phase of human testing in a range of cancers, both on its own and in combination with existing cancer immunotherapies. Sanofi on Monday said it would pay $68 a share in cash for Synthorx, a 172% premium to the smaller company’s closing share price Friday.

    “This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation,” said Mr. Hudson, who is set to provide an eagerly awaited strategy update to investors Tuesday.

    Full Content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.